Latest news with #GIPR
Yahoo
2 days ago
- Business
- Yahoo
GIPR Announces Sale of Two Properties and Full Repayment of CMBS Loan
TAMPA, FL / / June 4, 2025 / Generation Income Properties, Inc. (NASDAQ:GIPR) ("GIPR" or the "Company"), today announced the successful sale of two assets-an Auburn University-occupied industrial building in Huntsville, Alabama, and a Starbucks-occupied retail property in Tampa, Florida-both of which were previously encumbered under a single commercial mortgage-backed securities (CMBS) loan. The sales resulted in the full repayment of the loan's approximately $10.5 million principal balance, leaving the Company's remaining CMBS-encumbered property-a 7-Eleven in Washington, D.C.-completely unleveraged. Said David Sobelman, CEO of GIPR, "These transactions represent a meaningful milestone in GIPR's continued efforts to streamline its balance sheet and strategically enhance its portfolio. The Company navigated a complex payoff process and addressed a number of administrative and timing constraints that arose in connection with the CMBS loan, which was serviced by PNC Bank. With the CMBS loan now fully retired and these sales complete, GIPR is positioned to move forward with a cleaner capital structure and enhanced operational flexibility." About Generation Income Properties Generation Income Properties, Inc., located in Tampa, Florida, is an internally managed real estate investment trust formed to acquire and own, directly and jointly, real estate investments focused on retail, office and industrial net lease properties located primarily in densely populated submarkets throughout the United States. Additional information about Generation Income Properties, Inc. can be found on the Company's corporate website: Forward-Looking Statements: This press release, whether or not expressly stated, may contain "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "intend," "expect," "plan," "should," "will," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These statements reflect the Company's expectations regarding future events and economic performance and are forward-looking in nature and, accordingly, are subject to risks and uncertainties. Such forward-looking statements include risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements which are, in some cases, beyond the Company's control and which could have a material adverse effect on the Company's business, financial condition, and results of operations. These risks and uncertainties include the risk that that the expected benefits of the above-described portfolio acquisition will not be realized or will not be realized within the expected time periods, as well as risks relating to general economic conditions, market conditions, interest rates, and other risks and uncertainties that are identified from time to in the Company's SEC filings which are available at The occurrence of any of these risks and uncertainties could have a material adverse effect on the Company's business, financial condition, and results of operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statement made by us herein speaks only as of the date on which it is made. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as may be required by law. Investor Contact: Investor Relationsir@ SOURCE: Generation Income Properties View the original press release on ACCESS Newswire
Yahoo
29-05-2025
- Business
- Yahoo
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, June 5, 2025 at 11:05 a.m ET Location: New York City Goldman Sachs 46th Annual Global Healthcare Conference Format: Fireside Chat Date and Time: Monday, June 9, 2025 at 4:00 p.m. ET Location: Miami Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at A replay of the webcasts will be archived on Terns' website for at least 30 days following the presentations. About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Contacts for Terns InvestorsKaytee Bock Zafereoinvestors@ MediaJenna UrbanCG Lifemedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET. A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at A replay of the webcast will be archived on Terns' website for at least 30 days following the event. About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Contacts for Terns InvestorsKaytee Bockinvestors@ MediaJenna UrbanCG Life media@ in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Antag Therapeutics expands senior team to support clinical progress
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics ('Antag' or 'the Company'), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company's next phase of growth following the recent initiation of a Phase 1 trial of its GIP receptor antagonist AT-7687. Dr Jens Chr. Norrild joins as Vice President, Head of Chemistry, Manufacturing and Controls (CMC); Dr Ayna Baladi Nejad as Director of Clinical Pharmacology; and Dr Imke Tiessen as Chief of Staff. Jens brings over 15 years of experience in drug development and CMC leadership. He most recently served as Chief CDMO Officer at Bioneer, where he was a member of the leadership team. Prior to this, he was Vice President of CMC & Quality at Cytoki Pharma. Earlier in his career, he held several roles at Novo Nordisk, including as CMC Project Director where he brought several obesity and diabetes drugs, including peptides, to the clinic. He holds a PhD in carbohydrate chemistry from the Technical University of Denmark (DTU) and a Master's degree in Organic Chemistry from University of Copenhagen. Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal Clinical Pharmacology Scientist at Novo Nordisk, having led several global programs for assets including monlunabant, a small molecule drug in development for weight management, and CagriSema, in development for type 2 diabetes and weight management. Prior to her roles in the biopharma industry, she held academic positions in Denmark, US, and France, with a research focus in neuroscience and psychiatry. She holds a PhD in Health and Medical Sciences from the University of Copenhagen. Imke joins Antag with more than five years of experience in leadership support from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, where she served as Senior Executive Assistant and Innovation Coordinator of the Center's newly established Innovation Team. She holds a PhD in Molecular Biology from the University of Copenhagen and an MSc in Molecular Biomedicine from the University of Münster, Germany. Jörg Möller, Chief Executive Officer of Antag Therapeutics said: 'We are pleased to welcome Jens, Ayna and Imke to Antag, each bringing deep expertise that will be instrumental as we progress our GIPR antagonist AT-7687 through the clinic. Their collective experience will help advance our mission to deliver a flexible, differentiated obesity treatment - one that goes beyond current GLP-1-based therapies by aiming to achieve and maintain weight loss without compromising tolerability.' -ENDS- About Antag Therapeutics Antag Therapeutics is a biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. For more information, please visit About AT-7687 The development of AT-7687 builds on the groundbreaking discovery of an endogenous GIPR antagonist by Professors Jens Juul Holst, renowned for his discovery of GLP-1, and Mette Rosenkilde. In addition to promising preclinical data, the therapeutic potential of AT-7687 is further supported by robust human genetic validation, demonstrating that reducing GIP receptor activity is associated with leanness. Contacts Antag Therapeutics Joerg Moeller, MD, PhD CEO, Antag Therapeutics Email: Antag Therapeutics Media Contacts ICR Healthcare Davide Salvi, Lucy Featherstone Email: antagtx@ in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management. The stock has been trading about 63% below its all-time high. Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years. At its beaten-down price, the stock offers an eye-popping 7.8% yield. If Pfizer continues its dividend-raising streak, investors who buy at recent prices could realize market-beating gains over the long run. Let's look a little closer at danuglipron, plus some bigger problems the company faces, to see if this stock could be a smart buy on the dip. The end of Pfizer's danuglipron program highlights just how risky the drug-development process can be. According to the company, it discontinued development after just one patient in a dose-optimization study experienced a liver injury that could have been caused by the experimental GLP-1 pill. The danuglipron program's termination is disappointing, but it won't be the end of Pfizer's attempt to develop blockbuster weight-management drugs. The company has an oral glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist in phase 2 trials. Investors will probably hear more about this candidate, tentatively named PF-07976016, down the road. A disappointing outcome for a weight-management candidate isn't anywhere near the top of Pfizer's list of problems. Investors should be far more concerned with an upcoming loss of patent-protected market exclusivity for Eliquis. Sales of the oral blood thinner it markets in partnership with Bristol-Myers Squibb rose to $7.4 billion, or 11.6% of total revenue last year. Eliquis is expected to lose patent-protected exclusivity in 2026, although generic competition in the U.S. market isn't expected to begin until 2028. Pfizer's second-largest revenue stream in 2024 could also start drying up soon. The Prevnar family of vaccines was responsible for over 10% of total sales last year. Prevnar 13 is expected to lose patent-protected exclusivity in the U.S. next year. Vyndaqel has been a strong growth driver for Pfizer but probably not for much longer. This treatment prevents heart damage caused by transthyretin (TTR) amyloidosis and grew sales by 64% to reach $5.4 billion last year. Bridge Bio and Alnylam are now marketing competing treatments for the limited population of TTR amyloidosis patients with heart damage. In addition to competing treatments, Vyndaqel is expected to face generic competition in the U.S. in 2028. Drug developers need to communicate with regulators at the Food and Drug Administration (FDA) before, during, and after they run clinical trials for new drug candidates. In the U.S., many of those regulators recently lost their jobs. In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief medical officer. Having the former CDER director on staff could be advantageous for Pfizer, but I'll be pleasantly surprised if the FDA completes new drug approvals at half the usual pace this year. According to reporting from STAT, more than a few FDA employees involved in the new drug approval process were among thousands recently fired from the agency. A crippled FDA could be a huge problem for Pfizer and its peers who must constantly launch new drugs to overcome exclusivity losses for established products. Many investors expect pharmaceutical industry lobbyists to prevent the Trump administration from rendering CDER incapable of reviewing new drug applications at its usual pace. They could be right, but I won't support an investment thesis that relies on industry lobbyists protecting a regulatory agency. If you asked me a month ago, I would have called this stock a buy. In 2023, it earned FDA approval for nine new drugs and last year it reported over a dozen product approvals from the agency. With plenty of new products coming online, Pfizer had a good chance to overcome upcoming patent cliffs and maintain its dividend-raising streak. Now that the CDER has been dramatically downsized, it's probably best to assume the worst. I'll be avoiding this and all drugmaker stocks until we see proof that a much smaller FDA can continue approving new drugs at the usual pace. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $495,226!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $679,900!* Now, it's worth noting Stock Advisor's total average return is 796% — a market-crushing outperformance compared to 155% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, Bristol Myers Squibb, and Pfizer. The Motley Fool recommends BridgeBio Pharma. The Motley Fool has a disclosure policy. Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? was originally published by The Motley Fool Sign in to access your portfolio
